Evotec Signs Agreement with Hypha Discovery for access to Hypha’s high quality natural product screening collection to Further Enhance Its Lead Identification Platform
18 March 2010
– Evotec gains access to Hypha’s high quality natural product screening collection, MycoDiverse™ – Die deutsche Version dieser Pressemitteilung finden Sie hier. firstname.lastname@example.org | www.evotec.com Hamburg, Germany – 18 March 2010: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has signed an agreement with Hypha Discovery Ltd. Under the terms of the agreement, Evotec will be able to provide its screening clients with access to Hypha’s MycoDiverse™ natural product (hyperlink to R&D) collection for use as part of its hit and lead identification services. Furthermore, following screening, Evotec could leverage its capabilities and expertise in natural product chemistry and medicinal chemistry to optimise promising hit compounds.
The MycoDiverse™ collection, which is unexploited in most therapeutic areas, contains samples of high chemical novelty. This,
allied with Evotec’s recognised expertise and proprietary technologies in assay development, screening and medicinal chemistry, creates a comprehensive platform for lead generation via natural product screening.
Dr Liam Evans, Chief Executive Officer of Hypha Discovery stated: “Evotec is a world leading provider of high throughput screening services to pharmaceutical and biotechnology companies, and as such this strategic partnership provides new and exciting opportunities to find novel drug leads resulting from our breakthrough fungal fermentation technology.”
Dr Mark Ashton, Executive Vice President, Business Development of Evotec commented: “We are continually looking at ways to enhance Evotec’s offering to its customers. We see access to Hypha’s high quality natural product collection as a logical step towards offering our customers further choices for lead identification. We feel that our ability to offer the screening of natural products is complementary to also providing access to our high quality, small molecule library.”
For further information, please contact
Dr Werner Lanthaler
Chief Executive Officer
+49.(0)40.560 81-333 Fax
Evotec AG (Headquarters)
22525 Hamburg, Germany
Chief Executive Officer
+44 (0)1895 814585
+44 (0)5603 419058 Fax
The Russell Building No.1
Brunel Science Park, Uxbridge
Middlesex UB8 3PQ, UK
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialised platform that can drive new innovative small molecule
compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including for example a strategic alliance with Roche for the EVT 100 compound family, subtype selective
NMDA receptor antagonists for use in treatmentresistant depression. For additional information please go to www.evotec.com.
About Hypha Discovery Ltd
Hypha is a natural products screening company, focusing on theproduction of biologically useful compounds from Higher Fungi, using proprietary stimulatory fermentation methods. The company collaborates with drug discovery companies through the supply of
the MycoDiverse™ natural products library a collection of 10,000 extracts and fractions with unusually high chemical novelty. Hypha has a pipeline of oncology and antiinfective pre-clinical projects from the MycoDiverse™ library, led by the HD148 series of mTOR kinase inhibitors, a synthetic series inspired by the discovery of a unique family of anticancer compounds from a tropical mushroom. Based in London, the company also provides custom fermentation and compound purification contract services to other biotechnology companies. Please visit www.hyphadiscovery.co.uk for more information.
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about our expectations and assumptions concerning our strategic collaborations, our regulatory, clinical and business strategies, the progress of our clinical development programmes and management’s plans, objectives and strategies.
These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured; the risk that we will not achieve the anticipated benefits of our collaborations, partnerships and acquisitions in the timeframes expected, or at all; risks relating to our ability to advance the development of product candidates currently in the pipeline or in clinical trials; our inability to further identify, develop and achieve commercial success for new products and technologies; the risk that competing products may be more successful; our inability to interest potential partners in our technologies and products; our inability to achieve commercial success for our products and technologies; our inability to protect our intellectual property and the cost of enforcing or defending our intellectual property rights; our failure to comply with regulations relating to our products and product candidates, including FDA requirements; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally.
The list of risks above is not exhaustive. Our most recent Annual Report on Form 20-F, filed with the Securities and Exchange Commission, and other documents filed with, or furnished to the Securities and Exchange Commission, contain additional factors that could impact our businesses and financial performance. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.